Ethyl (E)-7-[4-(4′-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate | CAS:148901-69-3

We serve Ethyl (E)-7-[4-(4′-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate CAS:148901-69-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Ethyl (E)-7-[4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate

Chemical Name:Ethyl (E)-7-[4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate
CAS.NO:148901-69-3
Synonyms:Ethyl (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-5-hydroxy-3-oxohept-6-enoate
Molecular Formula:C27H26FNO4
Molecular Weight:447.49800
 
Physical and Chemical Properties:
Density:1.268
Boiling point:651.3ºC
Flash point:347.7ºC
Index of Refraction:1.631
 
Specification:
Appearance:Off-white to slight yellow crystalline powder
Assay:≥98.0%
Loss on drying:≤1.0%
Residue on ignition:≤0.2%
Relative substance:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediates of Rosuvastatin Calcium



Contact us for information like Ethyl (E)-7-[4-(4′-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethyl (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-5-hydroxy-3-oxohept-6-enoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethyl (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-5-hydroxy-3-oxohept-6-enoate Use and application,Ethyl (E)-7-[4-(4′-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate technical grade,usp/ep/jp grade.


Related News: Chinese nationals coming from China and connecting through another foreign airport will be denied travel. Those with pre-clearance are exempted.6-chloro-2-methyl-3-nitropyridine manufacturer The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.5-Bromopentan-1-ol supplier Countries across Asia, Europe, Australia and North America have also had confirmed cases, including the UK.2-Fluoro-6-methylnicotinonitrile vendor Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm.